Search research articles
Contact Us
Filters
Showing results (481-490 of 584) with videos related to
Page
of 59
Sort By:
American Journal of Hematology
|
August 18, 2017
First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY
Stuart L Goldberg, Jorge E Cortes, Carlo Gambacorti-Passerini, et al.
Cancer
|
April 8, 2017
Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation
Franck E Nicolini, Grzegorz W Basak, Dong-Wook Kim, et al.
Leukemia
|
August 21, 2023
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial
Mikkael A Sekeres, Pau Montesinos, Jan Novak, et al.
Blood Advances
|
January 4, 2018
Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis
Prajwal Boddu, Hagop M Kantarjian, Guillermo Garcia-Manero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 2, 2017
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
Jorge E Cortes, Carlo Gambacorti-Passerini, Michael W Deininger, et al.
American Journal of Hematology
|
August 4, 2018
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results
Jorge E Cortes, B Douglas Smith, Eunice S Wang, et al.
Cancer
|
January 15, 2015
Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up
Jorge E Cortes, Hagop M Kantarjian, Delphine Rea, et al.
Leukemia Research
|
June 3, 2017
Corrigendum to "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study" [Leuk. Res. 50 (Nov) (2016) 123-131. PubMed PMID: 27736729]
Ronan T Swords, Peter L Greenberg, Andrew H Wei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 10, 2010
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia
Farhad Ravandi, Jorge E Cortes, Daniel Jones, et al.
Leukemia Research
|
August 19, 2003
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia
Francis J Giles, Paula M Fracasso, Hagop M Kantarjian, et al.
Page
of 59
Search research articles
Search
Showing results (481-490 of 584) with videos related to
Sort By:
Page
of 59
American Journal of Hematology
|
August 18, 2017
First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY
Stuart L Goldberg, Jorge E Cortes, Carlo Gambacorti-Passerini, et al.
Cancer
|
April 8, 2017
Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation
Franck E Nicolini, Grzegorz W Basak, Dong-Wook Kim, et al.
Leukemia
|
August 21, 2023
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial
Mikkael A Sekeres, Pau Montesinos, Jan Novak, et al.
Blood Advances
|
January 4, 2018
Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis
Prajwal Boddu, Hagop M Kantarjian, Guillermo Garcia-Manero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 2, 2017
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
Jorge E Cortes, Carlo Gambacorti-Passerini, Michael W Deininger, et al.
American Journal of Hematology
|
August 4, 2018
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results
Jorge E Cortes, B Douglas Smith, Eunice S Wang, et al.
Cancer
|
January 15, 2015
Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up
Jorge E Cortes, Hagop M Kantarjian, Delphine Rea, et al.
Leukemia Research
|
June 3, 2017
Corrigendum to "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study" [Leuk. Res. 50 (Nov) (2016) 123-131. PubMed PMID: 27736729]
Ronan T Swords, Peter L Greenberg, Andrew H Wei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 10, 2010
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia
Farhad Ravandi, Jorge E Cortes, Daniel Jones, et al.
Leukemia Research
|
August 19, 2003
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia
Francis J Giles, Paula M Fracasso, Hagop M Kantarjian, et al.
Page
of 59